Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract...

Area of Science:

• Oncology
• Gastroenterology
• Cancer Stem Cell Biology

Background:

• Biliary tract cancer (BTC) is an aggressive malignancy with poor outcomes.
• Cancer stem cells (CSCs) contribute to BTC's resistance to therapy and recurrence.
• Transgelin-2 (TAGLN2) is overexpressed in BTC CSCs, suggesting a potential therapeutic target.

Purpose of the Study:

• To investigate the role of TAGLN2 in BTC progression and CSC characteristics.
• To evaluate TAGLN2 as a potential diagnostic biomarker for BTC.
• To assess the therapeutic potential of targeting TAGLN2 in BTC.

Main Methods:

• TAGLN2 was suppressed using RNA interference in BTC cell lines.
• Effects on cell proliferation, migration, invasion, and CSC properties were assessed.
• TAGLN2 expression was analyzed in patient tissues and plasma using western blotting and immunohistochemistry.

Main Results:

• TAGLN2 suppression reduced BTC cell growth, migration, invasion, and CSC features.
• High TAGLN2 expression in tumor stroma correlated with shorter disease-free survival.
• Plasma TAGLN2 levels were elevated in BTC patients and showed higher diagnostic accuracy than CA19-9.

Conclusions:

• TAGLN2 promotes BTC growth, motility, and stemness, impacting treatment resistance.
• Targeting TAGLN2 may represent a viable therapeutic strategy for advanced BTC.
• TAGLN2 shows promise as a novel, sensitive biomarker for BTC detection.